NEW YORK – T-Knife Therapeutics plans to begin a clinical trial this year of its PRAME-targeting armored T cell receptor (TCR) therapy, after the company confirmed on Tuesday that the European ...
Phase 1 ATLAS trial to evaluate TK-6302 in patients with advanced PRAME-positive solid tumors authorized for initiation SAN ...
New antibody-drug conjugates (ADCs) developed at Institute of Science Tokyo combine a CD4 mimic with neutralizing antibodies ...
New research from Memorial Sloan Kettering Cancer Center (MSK) finds the TCA cycle’s waste-management function may present an ...
Study dissects HIV reservoir clones that persist on ART, revealing how CD8+ T cells and resistance pathways could be ...
DOH said that a person living with HIV who takes antiretroviral medication consistently and correctly cannot transmit the ...
Even with treatment interruption after initiation of antiretroviral therapy (ART) at birth, aviremia could still be ...
Scientists isolated and grew rare HIV reservoir clones that allow the virus to persist despite therapy. The study shows that ...
Lung cancer cells are able to take advantage of a person’s immune system, specifically T cells, to protect the tumor, ...
Excerpted with permission from the publisher The Emperor of All Maladies: A Biography of Cancer (Revised Edition, 2026), ...
A new study has overcome a long-standing challenge: how to isolate and study elusive HIV-infected cells called authentic ...
Studies have demonstrated a critical role of the cytokines thymic stromal lymphopoietin (TSLP), IL-33, and IL-25, produced by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results